Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 3/20 | 0.56 |
| ▸ | IL4I1 | Q96RQ9 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 3/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24852008 | 0.86 | GUSB (0.51) | GUSBIL4I1KDM4ECYP1A2HSD17B10 | |
| SCHEMBL24852000 | 0.83 | EGFR (0.55) | GUSBIL4I1HSD17B10EGFRALDH1A1 | |
| SCHEMBL24851921 | 0.80 | GUSB (0.54) | GUSBIL4I1KDM4EEGFRERBB2 | |
| SCHEMBL24852002 | 0.80 | IL4I1 (0.44) | GUSBIL4I1KDM4ECYP1A2HSD17B10 | |
| SCHEMBL24851794 | 0.80 | GUSB (0.47) | GUSBIL4I1KDM4EEGFRALDH1A1 | |
| SCHEMBL24852013 | 0.79 | GUSB (0.48) | GUSBIL4I1KDM4ECYP1A2HSD17B10 | |
| SCHEMBL24852507 | 0.78 | IL4I1 (0.51) | IL4I1KDM4ECYP1A2HSD17B10EGFR | |
| SCHEMBL24851962 | 0.78 | IL4I1 (0.51) | IL4I1KDM4ECYP1A2HSD17B10EGFR | |
| SCHEMBL24852005 | 0.78 | GUSB (0.47) | GUSBIL4I1HSD17B10EGFRERBB2 | |
| SCHEMBL24852006 | 0.77 | EGFR (0.52) | GUSBIL4I1CYP1A2EGFRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | GUSB 573/4885IL4I1 1/4885KDM4E 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.